Alendronate is commonly used for the treatment of postmenopausal osteoporosis; however, the underlying pathological molecular mechanisms of its action remain unclear. In the present study, the alendronate-treated signaling pathway in bone metabolism in rats with ovariectomy induced by osteoporosis was investigated. Rats with osteoporosis were orally administered alendronate or phosphate-buffere...

BACKGROUND Alendronate is a bisphosphonate that is approved to reduce bone loss in glucocorticoid treated patients. In this paper, we present a case of femoral fracture following the use of Alendronate. CASE PRESENTATION A- 46 year old woman who was a known case of hemolytic anemia has been treated by prednisolone (with different doses from 7.5 to 75 mg/day), calcium-D 500 mg/day and alendron...

Accurate determination of urinary stone composition has significant bearing on understanding pathophysiology, choosing treatment modalities and preventing recurrence. A need exists for improved methods to determine stone composition. Urine of 31 patients with known renal calculi was examined with nanoscale flow cytometry and the calculi collected during surgery subsequently underwent petrograph...

Evidence • FLEX1: An RCT of 1099 postmenopausal women with osteoporosis (mean age 73, 60% with previous fracture, 4to 5-year use of alendronate) randomized to 5 mg or 10 mg of alendronate or placebo. After 5 additional years, bone mineral density (BMD) scores in the placebo group were lower than in the alendronate group, and total nonvertebral fractures and total vertebral fractures were not st...

BACKGROUND We evaluated whether patients with osteoporosis treated with long-term alendronate have a response to parathyroid hormone treatment and whether short, three-month cycles of parathyroid hormone therapy could be as effective as daily administration. METHODS We randomly assigned 126 women with osteoporosis who had been taking alendronate for at least 1 year to continued alendronate pl...

BACKGROUND Treatment guidelines recommend drug treatment to prevent fractures for some postmenopausal women who have low bone mass (osteopenia) but do not have osteoporosis or a history of clinical fractures. OBJECTIVE To estimate the societal costs and health benefits of alendronate drug treatment to prevent fractures in postmenopausal women with osteopenia. DESIGN Markov model with 8 heal...

Osteoporosis most commonly affects postmenopausal women, placing them at a significant risk of fractures. In particular, hip fractures are an important cause of mortality and morbidity among postmenopausal women. Anti-resorptive therapies that produce greater decreases in bone turnover markers together with greater increases in bone mineral density (BMD) are associated with greater reductions i...

background: bisphosphonates (bps) are used extensively for managing the osteoporosis. there are some controversies on atypical fractures of femur that associated with increase in cortical thickness (ct) and bps' use. in this study, the effects of alendronate consumption were studied on femoral ct as a predictor for atypical fracture.   methods: forty nine post-menopausal women aged 50-70 years ...

BACKGROUND Long-term treatment of cats with ionized hypercalcemia using alendronate has not been evaluated. HYPOTHESIS/OBJECTIVES Alendronate is well tolerated in treatment of ionized hypercalcemia in cats. ANIMALS A total of 12 cats with ionized hypercalcemia. METHODS Prospective study of 12 cats with ionized hypercalcemia of idiopathic origin was identified by telephone and email commun...

BACKGROUND/AIMS This study was performed to compare the mucosal findings after esophagogastroduodenoscopy in two groups before and after the use of alendronate only and following administration of the enteric-coated alendronate (5 mg) and calcitriol (0.5 µg) combined drug (Maxmarvil, Yuyu Co.). METHODS The study population consisted of 33 postmenopausal healthy female volunteers, aged 50 to 7...